AEMD Profile
Aethlon Medical, Inc., a pioneering medical technology company headquartered in San Diego, California, is dedicated to developing innovative products for the diagnosis and treatment of life-threatening diseases in the United States. Established in 1999, the company has made significant strides in the medical field with its flagship product, the Aethlon Hemopurifier. This clinical-stage immunotherapeutic device is designed to remove tumor-derived exosomes and life-threatening viruses, including the COVID-19 virus, its associated variants, and related exosomes, from the human circulatory system.
The Aethlon Hemopurifier represents a breakthrough in medical technology, offering a novel approach to enhancing the body’s ability to fight off serious diseases. By targeting and eliminating harmful pathogens and cancer-promoting exosomes, the device supports the immune system in combating infections and malignancies more effectively. This technology has shown promise in clinical studies, positioning Aethlon Medical at the forefront of advancements in therapeutic apheresis and extracorporeal blood purification.
In addition to its focus on the Hemopurifier, Aethlon Medical is actively involved in collaborative research efforts to expand the potential applications of its technology. The company has partnered with the University of Pittsburgh Medical Center Hillman Cancer Center to conduct studies related to head and neck cancer. This collaboration aims to explore the efficacy of the Hemopurifier in reducing the tumor burden and improving treatment outcomes for cancer patients, thereby broadening the therapeutic scope of the device.
Aethlon Medical, Inc. is committed to addressing some of the most pressing health challenges through cutting-edge technology and strategic collaborations. With a robust pipeline of innovative therapies and ongoing research partnerships, the company is well-positioned to contribute significantly to the medical field. Aethlon’s mission is to develop solutions that enhance patient care and improve survival rates for individuals battling life-threatening conditions, reaffirming its role as a leader in the biotherapeutics sector.
|
